#PSMA
How does PSMA PET fit into prostate cancer imaging and management?

Explore clinical foundations this week as part of Applied Radiology's 3-part webinar series.

📅 Nov 12, 17 & 24 🔗 bit.ly/4BQ1frA
November 10, 2026 at 11:30 PM
2024 Top-Read Article in @ACSPublications: A bispecific PSMA/GRPR heterodimer combines PSMA-617 and RM2, showing dual tumour targeting, enhanced uptake & promising PK properties in preclinical studies: doi.org/10.1021/acsm...
Author: Christos Liolios (University of West Attica)
Synthesis and Preclinical Evaluation of a Bispecific PSMA-617/RM2 Heterodimer Targeting Prostate Cancer
Abstract. Prostate-specific membrane antigen (PSMA) and gastrin-releasing peptide receptor (GRPR) have been used for diagnostic molecular imaging/therapy o
doi.org
November 11, 2026 at 1:19 PM
📢 Join Applied Radiology TODAY for a FREE Expert Forum Webinar featuring Elizabeth Hawk, MD, who will explore the foundations and evolving role of PSMA PET imaging in prostate cancer.

🔗 Still plenty of time to register: bit.ly/3Xl17k0
November 12, 2026 at 2:00 PM
PSMA calls for early sugar export, deregulation of industry
LAHORE, Nov 11 (APP):Pakistan Sugar Mills Associat

https://en.tezkhabar.tv/psma-calls-for-early-sugar-export-deregulation-of-industry/
#TezkhabarNews #Tezkhabar #News #Live #PakistanNews #Pakistan #Headline #NewsHeadline #LiveNews #breaki
November 11, 2026 at 5:56 PM
FDA Issues Breakthrough Therapy Designation for Emerging #PSMA PET Agent in Men with Suspected PCa Recurrence
www.diagnosticimaging.com/view/fda-bre...
#radiology #RadRes #NuclearMedicine #ProstateCancer
November 12, 2026 at 12:36 PM
64Cu-SAR-bisPSMA received breakthrough therapy designation from the @fda.gov for PET of PSMA+ lesions in patients with prostate cancer and suspected biochemical recurrence #pcsm #oncology

Read more: www.onclive.com/view/fda-gra...
November 12, 2026 at 4:17 PM
Prostate cancer can change during treatment, and so can the best options for patients. Experts explain how repeat genetic testing and PSMA PET scans may help identify new targeted treatment opportunities.

www.onclive.com/view/retesti...

#ProstateCancer #PrecisionMedicine #TCSC
Retesting Strategies and PSMA PET Selection in Advanced Prostate Cancer | OncLive
The panelists outline when to retest patients with prostate cancer, since tumors evolve under treatment and a first genomic test is only a snapshot.
www.onclive.com
November 12, 2026 at 9:55 AM
Addition of 68GA-PSMA-11 PET/CT to MRI in the Prostate Cancer Diagnostic Pathway: Addressing an Unmet Need

🔗 Read the full article: bit.ly/4AzYI3E

mpMRI has improved the diagnostic pathway for suspected prostate cancer and is now widely used before biopsy. However, important gaps remain...
November 14, 2026 at 1:00 AM
A key part of Port State Measures is clearly communicating the systems and processes to industry users. I'm proud to be working with the Federated States of Micronesia 🇫🇲 as they work toward ratifying the PSMA.
norma.fm/port-state-m...
Port State Measures - NORMA
National Oceanic Resource Management Authority
norma.fm
November 12, 2026 at 10:31 PM
It’d be neat to have a US senator with some understanding of complex systems and agent based modeling.
November 5, 2026 at 1:12 PM
2/5 The pharma giant saw Phase 3 readouts finish on malaria (KLU156), IgA nephropathy (LNP023), and castrate-resistant prostate cancer (177Lu-PSMA-617) between Nov.

2–6.

Meanwhile, a Phase 4 fascioliasis trial wrapped and a Phase 2 MS study remains active.
November 9, 2026 at 2:25 PM
There are probably 100,000 prostatectomies a year in the USA. The field is doing its best with a very variable, personal kind of cancer.

I trust my doctors, not this nonsense.

That said, yeah, everyone should get a PSMA PET before deciding initial treatment. On that, I can agree.
November 9, 2026 at 3:36 AM
It’s weird, I’ve thought for years how it would have been better to have gotten a PSMA PET before my RALP. Just this week, I’m happy I didn’t. Cuz treatment would have been escalated and now, I might not need any.
I may never have needed any. But that’s a hard road, mentally.
November 9, 2026 at 3:48 AM
In this CME activity, Dillon Cockrell, MD, highlights how ¹⁷⁷Lu-PSMA-617 is reshaping treatment for patients with metastatic castration-resistant prostate cancer.

Earn CME: clinical.med-iq.com/activity/the...
November 6, 2026 at 1:37 PM
🔬 PSMA PET: Clinical Foundations

Join K. Elizabeth Hawk, MD, of Stanford Medicine, for Part 1 of Applied Radiology's free PSMA PET webinar series.

📅 Nov 12 | 2 PM ET
🔗 bit.ly/4yBIIN4
November 5, 2026 at 2:00 PM
🏆 Un proyecto conjunto de la #UPM
y el Hospital 12 de Octubre gana el I Premio Nacional de Teragnosis.
Prelude-PSMA investiga cómo anticipar la eficacia de un tratamiento contra el cáncer de próstata mediante IA e imágenes diagnósticas.
Lee la noticia completa: short.upm.es/e0ewo

#somosUPM
November 6, 2026 at 1:35 PM
I’ve been so ground down by the system that I don’t have any energy to shop around. I’ve had four PSMA PET scans and another CT and two MRIs in the last 18 months. I’ve met with countless oncologists, each with their own take on my “unusual” case…I just need to get this done and keep moving.
November 5, 2026 at 6:38 AM
Got a PSMA PET Quadra Scan???
November 3, 2026 at 3:21 AM
In my lifetime:

Prostate cancer PSA test invented when I was 25 years old

First prostate cancer PSMA PET scan in the world carried out when I was 51 years old

Lutetium 177 therapy approved when I was 61 years old
November 4, 2026 at 7:44 AM
Despite a lack of responses in the phase 2 LASER trial, Praful Ravi, MB, BChir, MRCP, of @danafarber.bsky.social explains how the outcome could help inform future research with radioligand therapy in advanced RCC #kcsm #oncology www.onclive.com/view/lutetiu...
Lutetium Lu 177 Vipivotide Tetraxetan Yields No Responses in PSMA+ ccRCC | OncLive
Praful Ravi, MB, BChir, MRCP, discusses the LASER futility readout, PSMA heterogeneity in clear cell RCC, and next steps for radiopharmaceuticals.
www.onclive.com
November 3, 2026 at 3:59 PM
Um dos principais alvos dessa tecnologia é a proteína PSMA, encontrada em maior quantidade nas células tumorais. Exames de PET conseguem mapear essas lesões, permitindo o uso de substâncias como o lutécio-177 para atingir a doença diretamente.
November 3, 2026 at 3:00 AM
🚀 A targeted #EV strategy for #prostate #cancer!
#PSMA-engineered #EVs deliver #siADAM9 to inhibit tumor growth, #migration, and #stemness while enhancing #androgen-targeted #therapy.
A promising step toward precision EV therapeutics! 🧬
🔗 www.oaepublish.com/articles/evc...
@labogden.bsky.social
November 3, 2026 at 2:32 AM
10 years ago PSMA PET scans did not exist...
November 1, 2026 at 9:08 PM
Chau, Biswas, Wagle, Maeder, Leapman, Yu, Bhattacharya: Spatial Atlas-Informed Loss Ensembles for Whole-Body PSMA PET/CT Metastasis Segmentation https://arxiv.org/abs/2610.40834 https://arxiv.org/pdf/2610.40834 https://arxiv.org/html/2610.40834
November 2, 2026 at 6:39 AM
adultos con CPRCm positivo para el antígeno de membrana específico de próstata (PSMA). Está disponible en España desde el 1 de enero de 2026, financiado e indicado en pacientes que han recibido tratamiento previo con inhibidores de la vía
November 2, 2026 at 7:37 AM